Episodes
Friday Feb 02, 2024
Friday Feb 02, 2024
Most clinical settings now use oscillometric BP devices to measure patients’ BP, and over half of people with hypertension (HTN) use a home BP monitor. Can we trust these BP readings if an inappropriate cuff size was used? How will this impact the way we assess BP control?
Guest Authors: Vincent Lam, PharmD and Kathleen Pincus, PharmD, BCPS, BCACP, CDCES
Music by Good Talk
Friday Oct 20, 2023
Friday Oct 20, 2023
Less than 1 in 4 patients with hypertension in the United States have achieved their blood pressure (BP) goal, according to the CDC. Many clinicians only think of changing medications if a patient is having an intolerance to the current regimen. However, individual patients might respond differently to each of the four major anti-hypertensive medication classes and, if we could determine in advance which class(es) would lower the blood pressure the most, we could minimize the number of medications eventually needed to attain control.
Guest Author: Anthony Ishak, PharmD, BCPS
Music by Good Talk
Tuesday Sep 05, 2023
Beyond Statins: Approaches to Lipid Lowering in 2023
Tuesday Sep 05, 2023
Tuesday Sep 05, 2023
This episode is a collaboration between the ACCP Ambulatory Care Practice and Research Network (PRN) ... and iForumRx.org.
The treatment of dyslipidemia has gotten a lot more complex in recent years as we now have several non-statins that can substantially lower LDL cholesterol and reduce cardiovascular event rates - including PCSK9 monoclonal antibodies, ezetimibe, bempedoic acid, and inclisiran. When and how should we be using these agents?
Panelists: David Dixon, PharmD, BCACP, CDCES, CLS; Kathryn Litten, PharmD, BCACP; and Tomasz Jurga, PharmD, BCPS, BCACP, BCCP, CDCES
Produced by Jonathan Hughes, PharmD, BCPS, BCACP and Anna Love, PharmD, BCACP
Music by lemonmusicstudio from Pixabay
Friday Aug 25, 2023
Fixed Dose or Treat-to-Target: Does LODESTAR Guide Us on Statin Management?
Friday Aug 25, 2023
Friday Aug 25, 2023
There has been a long-standing debate about the optimal approach to statin use, including whether we should initiate therapy using a “fixed-dose”, high-potency statin, or whether we should “start low and go slow” by titrating the dose to a specific LDL-C target. The LODESTAR study was designed to determine if treating LDL-C to a target level produces similar cardiovascular outcomes when compared to a fixed-dose approach.
Guest Authors: Dawn Fuke, PharmD, BCPS and Catherine Behret, PharmD, BCACP
Music by Good Talk
Friday Jun 09, 2023
Is There a CLEAR Role for Bempedoic Acid in Cardiovascular Risk Reduction?
Friday Jun 09, 2023
Friday Jun 09, 2023
There are a variety of non-statin lipid-lowering medications with proven cardiovascular benefits; however, most of the evidence supporting their use has been as an adjunct with a statin. Bempedoic acid offers a novel mechanism of action to treat hypercholesterolemia. But is there a CLEAR role for bempedoic acid in the treatment and prevention of ASCVD in statin-intolerant patients?
Guest Authors: Sarah B. Edwards, PharmD and Briana Williams, PharmD, BCPS, BCACP
Special Guest: Joseph Saseen, PharmD, BCPS, BCACP
Music by Good Talk
Friday Apr 14, 2023
Friday Apr 14, 2023
You’ve probably encountered many patients who have experienced muscle symptoms after starting a statin. Statin-associated muscle symptoms (SAMS) contribute to treatment discontinuation and significantly increase cardiovascular (CV) adverse events and mortality. What strategies do you recommend to increase statin tolerance?
Guest Author: Rick Hess, PharmD, CDCES, BCACP
Music by Good Talk
Friday Mar 17, 2023
Complex Patient Case 2 - Managing Adverse Effects
Friday Mar 17, 2023
Friday Mar 17, 2023
Reason for Visit: The patient is here today for hypotension and diabetes follow-up. The primary care physician has consulted the clinical pharmacist regarding hypotension.
Chief Complaint: “I feel dizzy when I stand up and feel like my heart is racing. I have never passed out, but it feels like I might, and I usually have to sit back down."
Guest Authors: Kellie Ball, PharmD and Johnathon Proctor, PharmD
Expert Panelists: Morgan Weaver Godfrey, PharmD, BCPS and Richard J. Silvia, PharmD, BCPP
Friday Feb 03, 2023
Friday Feb 03, 2023
Hyperkalemia is a common electrolyte disorder in patients with CKD that can be exacerbated by renin-angiotensin-aldosterone system (RAAS) inhibitors. While hyperkalemia poses potential risks to patients with CKD, the potentially negative impact of discontinuing RAAS inhibitor therapy on long-term renal and cardiovascular outcomes in CKD patients is unclear.
Guest Author: Michelle A. Fravel, PharmD, BCPS
Music by Good Talk
Friday Dec 09, 2022
Is Icosapent Ethyl a QALY-ty Investment?
Friday Dec 09, 2022
Friday Dec 09, 2022
The landmark REDUCE-IT trial demonstrated that icosapent ethyl (IPE) 4 g daily significantly reduced cardiovascular events in high-risk patients when added to statin therapy, but is a fancy fish oil supplement really worth our coin?
Guest Authors: Joseph Nardolillo, PharmD, BCACP and Vivian Cheng, PharmD, BCPS, BCACP
Music by Good Talk
Thursday Oct 13, 2022
Top Ten Things Every Clinician Should Know About the 2022 Heart Failure Guidelines
Thursday Oct 13, 2022
Thursday Oct 13, 2022
The 2022 AHA/ACC/HFSA Heart Failure Guidelines is a much-needed update and consolidates previously published recommendations. In the written commentary we describe the top ten things every clinician should know about the 2022 AHA/ACC/HFSA Heart Failure Guidelines. This podcast episode highlights some of the key recommendations from the guidelines and addresses some of the practical implications.
Guest Authors: Madison Yates, PharmD and Megan Supple, PharmD, BCACP, CPP
Music by Good Talk